Drug adverse event reports (FAERS)

Warm autoimmune haemolytic anaemia

Drugs: TACROLIMUS, ALLOPURINOL, BISOPROLOL

SeriousHospitalizationOther seriousReport 26940056
Safetyreportversion
1
Safetyreportid
26940056
Primarysourcecountry
US
Occurcountry
US
Transmissiondateformat
102
Transmissiondate
20260709
Reporttype
1
Serious
1
Seriousnessdeath
2
Seriousnesslifethreatening
2
Seriousnesshospitalization
1
Seriousnessdisabling
2
Seriousnesscongenitalanomali
2
Seriousnessother
1
Receivedateformat
102
Receivedate
20260630
Receiptdateformat
102
Receiptdate
20260630
Fulfillexpeditecriteria
1
Companynumb
US-AVET LIFESCIENCES LTD-2026-AVET-000136
Primarysource
Reportercountry
US
Qualification
3
Sender
Sendertype
6
Senderorganization
EMCURE PHARMACEUTICALS LTD
Receiver
Receivertype
6
Receiverorganization
FDA
Patient
Patientonsetage
30
Patientonsetageunit
801
Patientsex
2
Reaction
  1. Reactionmeddraversionpt
    29.0
    Reactionmeddrapt
    Warm autoimmune haemolytic anaemia
    Reactionoutcome
    1
Drug
  1. Drugcharacterization
    1
    Medicinalproduct
    TACROLIMUS
    Drugbatchnumb
    Unknown
    Drugauthorizationnumb
    090402
    Drugstructuredosagenumb
    5
    Drugstructuredosageunit
    003
    Drugseparatedosagenumb
    1
    Drugintervaldosageunitnumb
    1
    Drugintervaldosagedefinition
    804
    Drugdosagetext
    5 MG DAILY
    Drugdosageform
    Immediate release capsule
    Drugindication
    Immunosuppression
    Actiondrug
    2
    Drugadditional
    1
    Activesubstance
    Activesubstancename
    TACROLIMUS
    Harmonized identifiers (openFDA)
    Application number
    ANDA210393, ANDA211688, ANDA203740, NDA050777, ANDA206662, ANDA215012, ANDA206651, ANDA090509, NDA050708, NDA210115, NDA050709, ANDA090802, ANDA200744, ANDA212387, ANDA091195, ANDA213112, ANDA212297, NDA206406, ANDA090596, ANDA090687, ANDA217108
    Brand name
    TACROLIMUS, PROGRAF, ENVARSUS XR
    Generic name
    TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES
    Manufacturer name
    Glenmark Pharmaceuticals Inc., USA, Accord Healthcare Inc., Ascend Laboratories, LLC, Padagis Israel Pharmaceuticals Ltd, NORTHSTAR RX LLC, Amneal Pharmaceuticals NY LLC, BPI Labs LLC, Quallent Pharmaceuticals Health LLC, Astellas Pharma US, Inc., Jubilant Cadista Pharmaceuticals Inc., E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC, Encube Ethicals, Inc., Dr. Reddy's Laboratories Limited, Stellon Biotech Inc., Biocon Pharma Inc., Veloxis Pharmaceuticals, Inc, Mylan Pharmaceuticals Inc., Strides Pharma Science Limited, Chengdu Suncadia Medicine Co., Ltd., Nexus Pharmaceuticals, LLC, Panacea Biotec Limited, CONCORD BIOTECH LIMITED, Ajenat Pharmaceuticals LLC
    Product NDC
    68462-534, 68462-881, 16729-421, 16729-422, 67877-278, 67877-279, 67877-280, 45802-390, 45802-700, 16714-098, 16714-099, 16714-100, 69238-2780, 69238-2781, 69238-2782, 54288-133, 54288-135, 54288-134, 82009-054, 82009-164, 82009-165, 0469-0607, 0469-0617, 0469-0657, 0469-3016, 0469-1230, 0469-1330, 59746-798, 59746-799, 59746-800, 0168-0416, 0168-0417, 21922-011, 68462-685, 68462-686, 68462-687, 55111-525, 55111-526, 55111-527, 16729-041 +30 more
    Product type
    HUMAN PRESCRIPTION DRUG
    Route
    TOPICAL, ORAL, INTRAVENOUS
    Substance name
    TACROLIMUS
    RxCUI
    313189, 314266, 198377, 198378, 313190, 1431971, 1431980, 1431985, 108513, 108514, 108515, 198379, 261134, 2052605, 2052609, 2052703, 2052704, 2665161, 2665162, 2665163, 1664434, 1664440, 1664456, 1664458, 1664461, 1664463
    SPL ID
    15dcd504-ee3e-4f0f-a765-55e31511641e, 23a804e6-2854-6b9b-e063-6394a90af669, 46ed8f56-e67b-4faa-9ad3-1c07ae46e8ac, ca08f41f-bc87-45bb-91b8-1d89adfba78f, 0e68684e-7947-40a2-b17c-7919e94163a5, 05c70395-3037-4e8a-be20-dd9f4aebbe06, f2e9bcc1-fc42-4fab-a6b2-aceaa77fb2b9, 3e44dd25-4ad2-6ddc-f77b-7a66fc7fb89a, e9157663-1515-4ba3-83b5-1622cf6f0f99, e39f4aa6-bc0f-413d-b855-3bf869c2e2ee, a63cc4f4-5aba-4e02-915a-5535f2b625aa, 9197a805-bb44-44b8-9ae7-d39a01acb1a7, 13e3f94c-d4c5-4b5b-a51a-0e87eadc5718, 706bafff-d629-291c-5ce5-83d74a638860, 3622f4f5-48bd-9035-e063-6294a90afac2, 53396094-b61b-4383-a680-82974cc9c159, 640e066c-f2a3-5fb2-4b55-4ac9aec0d31b, 163c129d-f4e2-484d-af96-c265c9a5e38c, 7d8a5bab-a744-4aa7-b28f-d0c2c5a53628, d4a7fb82-5ff6-4ffc-bec5-ff0d50347a9b, 102bdf7c-9d79-0124-e063-6394a90aced9, 44fc0987-ff9d-3099-e063-6394a90a7a55, 778cec6b-16f1-47b0-9c97-113ea026b5e5, 76ffdfc1-7f00-49da-9578-5352593b4830, 6b08720e-dc88-4731-8863-af564a293b5a
    SPL set ID
    c2d2e3a1-f346-4245-b445-6dd44e371180, 80e6817a-9b1e-4f0f-e053-2a91aa0a3d15, 55467f4b-8437-43a3-b6d9-1bc2a13b4c11, 6b601eaf-4f3a-4a8b-8cd8-1000defa9822, 875f4962-557e-4e12-ad7b-cb5fb6f2a65f, 4eb1b6bd-beec-4dd5-9a48-c93a9fe918b3, 3e8bc65e-8048-4073-8e45-570330603000, 23b7b4d7-1431-e9f2-43ba-eabd169dc2dd, 7f667de1-9dfa-4bd6-8ba0-15ee2d78873b, 651bd506-96b0-43e5-a4dd-db03bf9154c9, 1bf44a84-14fd-4f80-ad8a-99b1431d631f, 43b38551-6c5e-48a4-a453-9286f1c16b34, 4b310c6b-e035-4e44-9573-4001d58b2ad5, 61dee012-43af-0e9a-3843-9b9b91e022c4, bd447ffa-9196-4c3c-accf-5adf29b84665, 6b89e8a4-9f11-42e3-8e79-fe617e7c461f, 0a557ca9-b1a1-cf8f-a317-e4d8d4d6e60f, de2315b0-6344-43ac-9aea-3e3b68d828e7, 45af3eda-caaa-4478-9372-95aa65adc9b3, ed7d1495-3585-409d-94f1-b3d2469d222c, 08cf2861-2483-405d-a872-a88a5c235f9a, 9d502961-e9c0-4611-92bf-ce742a7b962c, bd9fea26-0236-d437-c7df-4b7636210875, 823b11cb-d873-4017-a861-d22d2c5a8a49, ca08d4aa-3de2-4a9d-9554-6288e5d36f29
    Package NDC
    68462-534-35, 68462-534-65, 68462-534-94, 68462-881-35, 68462-881-65, 68462-881-94, 16729-422-10, 16729-422-12, 16729-422-01, 16729-421-10, 16729-421-12, 16729-421-01, 67877-278-33, 67877-278-01, 67877-279-33, 67877-279-01, 67877-280-33, 67877-280-01, 45802-390-00, 45802-390-01, 45802-390-02, 45802-700-00, 45802-700-01, 45802-700-02, 16714-098-01, 16714-099-01, 16714-100-01, 69238-2780-3, 69238-2781-3, 69238-2782-3, 54288-135-01, 54288-134-01, 54288-133-01, 82009-164-01, 82009-054-01, 82009-165-01, 0469-0607-73, 0469-0617-73, 0469-0617-11, 0469-0657-73 +80 more
    UNII
    WM0HAQ4WNM
  2. Drugcharacterization
    1
    Medicinalproduct
    TACROLIMUS
    Drugbatchnumb
    Unknown
    Drugauthorizationnumb
    090402
    Drugstructuredosagenumb
    4
    Drugstructuredosageunit
    003
    Drugseparatedosagenumb
    1
    Drugintervaldosageunitnumb
    1
    Drugintervaldosagedefinition
    804
    Drugdosagetext
    4 MG, 1 DOSE PER 1D
    Drugdosageform
    Immediate release capsule
    Actiondrug
    2
    Drugadditional
    1
    Activesubstance
    Activesubstancename
    TACROLIMUS
    Harmonized identifiers (openFDA)
    Application number
    ANDA210393, ANDA211688, ANDA203740, NDA050777, ANDA206662, ANDA215012, ANDA206651, ANDA090509, NDA050708, NDA210115, NDA050709, ANDA090802, ANDA200744, ANDA212387, ANDA091195, ANDA213112, ANDA212297, NDA206406, ANDA090596, ANDA090687, ANDA217108
    Brand name
    TACROLIMUS, PROGRAF, ENVARSUS XR
    Generic name
    TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES
    Manufacturer name
    Glenmark Pharmaceuticals Inc., USA, Accord Healthcare Inc., Ascend Laboratories, LLC, Padagis Israel Pharmaceuticals Ltd, NORTHSTAR RX LLC, Amneal Pharmaceuticals NY LLC, BPI Labs LLC, Quallent Pharmaceuticals Health LLC, Astellas Pharma US, Inc., Jubilant Cadista Pharmaceuticals Inc., E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC, Encube Ethicals, Inc., Dr. Reddy's Laboratories Limited, Stellon Biotech Inc., Biocon Pharma Inc., Veloxis Pharmaceuticals, Inc, Mylan Pharmaceuticals Inc., Strides Pharma Science Limited, Chengdu Suncadia Medicine Co., Ltd., Nexus Pharmaceuticals, LLC, Panacea Biotec Limited, CONCORD BIOTECH LIMITED, Ajenat Pharmaceuticals LLC
    Product NDC
    68462-534, 68462-881, 16729-421, 16729-422, 67877-278, 67877-279, 67877-280, 45802-390, 45802-700, 16714-098, 16714-099, 16714-100, 69238-2780, 69238-2781, 69238-2782, 54288-133, 54288-135, 54288-134, 82009-054, 82009-164, 82009-165, 0469-0607, 0469-0617, 0469-0657, 0469-3016, 0469-1230, 0469-1330, 59746-798, 59746-799, 59746-800, 0168-0416, 0168-0417, 21922-011, 68462-685, 68462-686, 68462-687, 55111-525, 55111-526, 55111-527, 16729-041 +30 more
    Product type
    HUMAN PRESCRIPTION DRUG
    Route
    TOPICAL, ORAL, INTRAVENOUS
    Substance name
    TACROLIMUS
    RxCUI
    313189, 314266, 198377, 198378, 313190, 1431971, 1431980, 1431985, 108513, 108514, 108515, 198379, 261134, 2052605, 2052609, 2052703, 2052704, 2665161, 2665162, 2665163, 1664434, 1664440, 1664456, 1664458, 1664461, 1664463
    SPL ID
    15dcd504-ee3e-4f0f-a765-55e31511641e, 23a804e6-2854-6b9b-e063-6394a90af669, 46ed8f56-e67b-4faa-9ad3-1c07ae46e8ac, ca08f41f-bc87-45bb-91b8-1d89adfba78f, 0e68684e-7947-40a2-b17c-7919e94163a5, 05c70395-3037-4e8a-be20-dd9f4aebbe06, f2e9bcc1-fc42-4fab-a6b2-aceaa77fb2b9, 3e44dd25-4ad2-6ddc-f77b-7a66fc7fb89a, e9157663-1515-4ba3-83b5-1622cf6f0f99, e39f4aa6-bc0f-413d-b855-3bf869c2e2ee, a63cc4f4-5aba-4e02-915a-5535f2b625aa, 9197a805-bb44-44b8-9ae7-d39a01acb1a7, 13e3f94c-d4c5-4b5b-a51a-0e87eadc5718, 706bafff-d629-291c-5ce5-83d74a638860, 3622f4f5-48bd-9035-e063-6294a90afac2, 53396094-b61b-4383-a680-82974cc9c159, 640e066c-f2a3-5fb2-4b55-4ac9aec0d31b, 163c129d-f4e2-484d-af96-c265c9a5e38c, 7d8a5bab-a744-4aa7-b28f-d0c2c5a53628, d4a7fb82-5ff6-4ffc-bec5-ff0d50347a9b, 102bdf7c-9d79-0124-e063-6394a90aced9, 44fc0987-ff9d-3099-e063-6394a90a7a55, 778cec6b-16f1-47b0-9c97-113ea026b5e5, 76ffdfc1-7f00-49da-9578-5352593b4830, 6b08720e-dc88-4731-8863-af564a293b5a
    SPL set ID
    c2d2e3a1-f346-4245-b445-6dd44e371180, 80e6817a-9b1e-4f0f-e053-2a91aa0a3d15, 55467f4b-8437-43a3-b6d9-1bc2a13b4c11, 6b601eaf-4f3a-4a8b-8cd8-1000defa9822, 875f4962-557e-4e12-ad7b-cb5fb6f2a65f, 4eb1b6bd-beec-4dd5-9a48-c93a9fe918b3, 3e8bc65e-8048-4073-8e45-570330603000, 23b7b4d7-1431-e9f2-43ba-eabd169dc2dd, 7f667de1-9dfa-4bd6-8ba0-15ee2d78873b, 651bd506-96b0-43e5-a4dd-db03bf9154c9, 1bf44a84-14fd-4f80-ad8a-99b1431d631f, 43b38551-6c5e-48a4-a453-9286f1c16b34, 4b310c6b-e035-4e44-9573-4001d58b2ad5, 61dee012-43af-0e9a-3843-9b9b91e022c4, bd447ffa-9196-4c3c-accf-5adf29b84665, 6b89e8a4-9f11-42e3-8e79-fe617e7c461f, 0a557ca9-b1a1-cf8f-a317-e4d8d4d6e60f, de2315b0-6344-43ac-9aea-3e3b68d828e7, 45af3eda-caaa-4478-9372-95aa65adc9b3, ed7d1495-3585-409d-94f1-b3d2469d222c, 08cf2861-2483-405d-a872-a88a5c235f9a, 9d502961-e9c0-4611-92bf-ce742a7b962c, bd9fea26-0236-d437-c7df-4b7636210875, 823b11cb-d873-4017-a861-d22d2c5a8a49, ca08d4aa-3de2-4a9d-9554-6288e5d36f29
    Package NDC
    68462-534-35, 68462-534-65, 68462-534-94, 68462-881-35, 68462-881-65, 68462-881-94, 16729-422-10, 16729-422-12, 16729-422-01, 16729-421-10, 16729-421-12, 16729-421-01, 67877-278-33, 67877-278-01, 67877-279-33, 67877-279-01, 67877-280-33, 67877-280-01, 45802-390-00, 45802-390-01, 45802-390-02, 45802-700-00, 45802-700-01, 45802-700-02, 16714-098-01, 16714-099-01, 16714-100-01, 69238-2780-3, 69238-2781-3, 69238-2782-3, 54288-135-01, 54288-134-01, 54288-133-01, 82009-164-01, 82009-054-01, 82009-165-01, 0469-0607-73, 0469-0617-73, 0469-0617-11, 0469-0657-73 +80 more
    UNII
    WM0HAQ4WNM
  3. Drugcharacterization
    2
    Medicinalproduct
    ALLOPURINOL
    Drugbatchnumb
    Unknown
    Drugstructuredosagenumb
    100
    Drugstructuredosageunit
    003
    Drugseparatedosagenumb
    1
    Drugintervaldosageunitnumb
    1
    Drugintervaldosagedefinition
    804
    Drugdosagetext
    100 MG DAILY
    Actiondrug
    5
    Drugadditional
    3
    Activesubstance
    Activesubstancename
    ALLOPURINOL
    Harmonized identifiers (openFDA)
    Application number
    ANDA203154, ANDA212363, ANDA071450, ANDA204467, ANDA214443, NDA018832, NDA018877, ANDA217748, ANDA077353, ANDA018659, ANDA210117, ANDA215091, ANDA071587, NDA020298, ANDA211820, NDA016084, ANDA075798
    Brand name
    ALLOPURINOL, ALOPRIM
    Generic name
    ALLOPURINOL
    Manufacturer name
    Accord Healthcare Inc., Gland Pharma Limited, Sun Pharmaceutical Industries, Inc., Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc., Florida Pharmaceutical Products, LLC, Harman Finochem Limited, Indoco Remedies Limited, Actavis Pharma, Inc., Camber Pharmaceuticals, Inc., Chartwell RX, LLC, Mylan Pharmaceuticals Inc., Zydus Lifesciences Limited, Aurobindo Pharma Limited, NorthStar RxLLC, Dr. Reddy's Laboratories Limited, Fresenius Kabi USA, LLC, Mylan Institutional LLC, Zydus Pharmaceuticals (USA) Inc., Unichem Pharmaceuticals (USA), Inc., Rising Pharma Holdings, Inc., XLCare Pharmaceuticals Inc., Par Health USA, LLC
    Product NDC
    16729-134, 16729-135, 68083-380, 53489-156, 53489-157, 23155-693, 23155-694, 71921-240, 71921-242, 71921-241, 82638-112, 82638-113, 14445-170, 14445-171, 14445-172, 0591-5543, 0591-5544, 31722-252, 31722-253, 62135-516, 62135-517, 0378-0137, 0378-0181, 70771-1126, 70771-1127, 70771-1907, 59651-285, 59651-286, 16714-576, 16714-577, 55111-729, 55111-730, 65219-380, 67457-187, 70710-1209, 70710-1210, 70710-2009, 29300-349, 29300-350, 16571-883 +6 more
    Product type
    HUMAN PRESCRIPTION DRUG
    Route
    ORAL, INTRAVENOUS
    Substance name
    ALLOPURINOL, ALLOPURINOL SODIUM
    RxCUI
    197319, 197320, 252931, 245422, 261265
    SPL ID
    40820fd2-3759-d43f-e063-6394a90a7c93, 6a0eaf66-34ca-4ba5-a2c6-a3c369ddf30c, 57e38626-7a9d-4140-e063-6294a90acd2e, 43518352-e2b6-4133-97fc-860d3eeea074, 88cf17e7-9773-490a-992b-63525120cadc, 2b4201b6-c125-05d2-e063-6294a90a58c1, 7394738d-e6ca-4be9-9fb8-28702362abc5, f7e04d88-1d9b-47e6-a9ad-deb08af3c098, 2a7490a6-7492-4fe1-b0f5-0e22bd0d458a, 4b432cc5-11c8-4450-e063-6394a90a1053, 38f49ed2-9641-404b-8146-5555064b86e8, 183fab96-5c7b-4fcc-a475-5d1832bbf9c6, ef67cf70-5cf4-4b0d-86a5-c5af60228180, 0f560d11-3ba5-4dd4-8c20-ed9b43bfd69a, 15f5d0a0-98ae-aa59-3a4d-d20efebbc6f6, 2d2f4a09-b8bd-47ff-87db-a615efc34c4c, 35f241ea-eeb8-41b3-9596-be40eb9af06d, 95c7021b-a1a5-4a7f-aacf-275a64fe8b58, 25a9c596-5898-419b-b8bb-c2574fd23d54, 14a0ad9d-4145-4869-9d8d-747e5d7bfb44, 47dd9bd8-06e7-b387-e063-6294a90a74d4, 14909994-d957-4d81-a6e6-68d64107fd1b
    SPL set ID
    682dd8b8-fc6e-47c5-95b7-82d7ad96b750, 4839e842-511e-4c72-9153-2b7e4e1954e2, fd8f8b8b-f25e-46e9-969a-65363b66e09b, ad6950d4-2cdd-44ac-9b8a-120716460e70, 815af471-5985-4819-936d-1f5f3d871ef8, 0780dc78-d287-d5db-e063-6294a90aa1dd, 48a9a6c3-4604-421e-a323-1133888aaf76, a80fe56f-8d03-423f-8e2a-7ec8c9e5045b, 60750373-7146-455a-8d12-d0e32d2d4bc8, cdc3f33b-ff2b-4a84-a820-51a497fdf3d9, bdbf5ad4-86f2-4e9c-a51a-fb0c7220c480, 9232f484-a5f6-4c63-b7f4-b510d2827159, 311ca755-c022-4251-97eb-dd9be86a993f, 95a1ca8c-9855-4b11-92cd-6fdc144f0d3b, 19a138b8-d225-03e6-f762-abe71560204b, 2caf5eed-2408-4ce0-bd0d-04f4c90e434d, 10cc918f-aa44-415b-932d-2404695ac449, 8b926e62-3a9c-424a-833a-8169e55a1f15, e3face45-f920-46a0-b707-6a66aa9735bd, 30ad5ba2-1cef-4933-b104-0597f6a2aaa2, fc7973c8-d846-4eca-ab0d-d30228035ba2, fbac3b4f-dc23-4359-ac3f-2b3fdde41af2
    Package NDC
    16729-134-10, 16729-134-01, 16729-134-16, 16729-134-17, 16729-135-10, 16729-135-01, 16729-135-16, 16729-135-17, 68083-380-01, 53489-156-01, 53489-156-05, 53489-156-10, 53489-156-02, 53489-157-01, 53489-157-05, 53489-157-10, 53489-157-07, 53489-157-02, 23155-693-01, 23155-693-10, 23155-694-01, 23155-694-05, 71921-240-33, 71921-240-01, 71921-240-50, 71921-240-60, 71921-242-01, 71921-242-50, 71921-242-60, 71921-241-09, 82638-112-01, 82638-112-02, 82638-112-03, 82638-112-04, 82638-113-02, 82638-113-03, 82638-113-04, 14445-170-30, 14445-170-01, 14445-170-05 +96 more
    Nui
    N0000175698, N0000000206
    Pharm class epc
    Xanthine Oxidase Inhibitor [EPC]
    Pharm class moa
    Xanthine Oxidase Inhibitors [MoA]
    UNII
    63CZ7GJN5I, 428673RC2Z
  4. Drugcharacterization
    2
    Medicinalproduct
    BISOPROLOL
    Drugbatchnumb
    Unknown
    Drugstructuredosagenumb
    5
    Drugstructuredosageunit
    003
    Drugseparatedosagenumb
    1
    Drugintervaldosageunitnumb
    1
    Drugintervaldosagedefinition
    804
    Drugdosagetext
    5 MG DAILY
    Actiondrug
    5
    Drugadditional
    3
    Activesubstance
    Activesubstancename
    BISOPROLOL
    Harmonized identifiers (openFDA)
    Application number
    ANDA218303, ANDA075474
    Brand name
    BISOPROLOL
    Generic name
    BISOPROLOL FUMARATE
    Manufacturer name
    Micro Labs Limited, TruPharma, LLC
    Product NDC
    42571-470, 42571-471, 52817-270, 52817-271
    Product type
    HUMAN PRESCRIPTION DRUG
    Route
    ORAL
    Substance name
    BISOPROLOL FUMARATE
    RxCUI
    854901, 854905
    SPL ID
    4cbe74e3-3af3-2b98-e063-6294a90a1c2b, 2a9e4180-cb1c-f924-e063-6394a90a60c6
    SPL set ID
    c3ee566c-74c4-45f4-a947-526a7313e326, bba0bc2b-602f-4df1-a761-85bd3c80c7de
    Package NDC
    42571-470-30, 42571-470-01, 42571-470-05, 42571-471-30, 42571-471-01, 42571-471-05, 52817-270-10, 52817-270-30, 52817-271-10, 52817-271-30
    UNII
    UR59KN573L
Wholesale access for licensed clinicians.

Free to join: your NPI is checked against the federal registry at signup, then wholesale pricing and the professional shelves open.

How to read this: Each report says someone told FDA an event happened while a product was used. A report does not show the product caused it, and counts rise and fall with how many people report. Data from openFDA, FDA's public API. FDA says not to rely on it to make decisions about medical care and to treat every result as unvalidated; confirm against FDA's own record and the product labeling. Not medical or legal advice.